Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on October 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $350.0 million gross equity raise at $85.00 per share, strengthening Spyre’s funding runway.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $350.0 million gross equity raise at $85.00 per share, strengthening Spyre’s funding runway
- Potential additional 617,647 shares through the 30-day underwriter option, creating further dilution risk
- Proceeds targeted to Gastroenterology, Rheumatology, Dermatology and SPY072 late-stage development
- Funding supports preclinical studies, clinical trials, manufacturing and Phase 3 readiness
- Expected closing October 7, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.